The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Board of Directors
    • Staff & Volunteers
    • The Antibody Society’s Standing Committees
    • Advisors
    • Sponsors
    • James S. Huston Antibody Science Talent Award
  • Society meetings
    • Antibody Engineering & Therapeutics (US) 2020
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • Meeting reports
      • Keynote presentations
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2020
      • Antibody Engineering & Therapeutics Europe 2019
    • AIRR Community Meetings
    • FOCIS Symposia
    • Society-Funded Meetings
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Data Representation Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Minimal Standards Working Group
      • Software Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Antibodies in early-stage studies
    • Antibodies in late-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News You Should Know
    • Antibody therapeutics approved or in regulatory review in the EU or US
    • Research Resources
    • Education Resources
  • Career Center
  • Learning Center
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / About / Board of Directors / Paul Carter, Ph.D.

Paul Carter, Ph.D.

Dr. Paul Carter is a Genentech Fellow in the Antibody Engineering Department at Genentech, Inc.  His research passion is the quest for breakthrough antibody-based therapeutics that transform the lives of patients. In recent years his research interests have focused on how to make currently intractable targets druggable with antibodies -pursuit of the ‘high-hanging fruit’.

Dr. Carter co-initiated the humanization of antibodies at Genentech with a novel and patentable method. This technology has been utilized for the discovery of 9 approved antibody products that have been used to treat millions of patients worldwide. Paul and collaborators created ‘knobs-into-holes’ technology used in a one-armed antibody and 5+ bispecific antibodies that have reached clinical trials. He also developed a common light chain technology used by several different companies for generating bispecific antibodies, including 1 approved product. He invented technologies for high-level expression of antibody Fab fragments in E. coli used for 1 approved antibody product.

He has authored or co-authored 117+ scientific publications that together have been cited 19,800+ times (h-index of 62+). He is an inventor or co-inventor on 48+ granted US patents and 59+ published US patent applications. He has co-organized 18+ international conferences on antibody engineering and antibody therapeutics. He has delivered 119+ conference presentations and invited lectures including 12+ keynote presentations.

Dr. Carter received a B.A. in Natural Sciences from Cambridge University in 1982 and his Ph.D. in 1986 under Sir Greg Winter, Ph.D. at the MRC Laboratory of Molecular Biology in Cambridge.  From 1986-1989 he was a Postdoctoral Fellow with Dr. Jim Wells at Genentech.

He has over 30 years of biotechnology experience: Genentech (1986-2000 and 2010-present), Immunex/Amgen (2000-2003), Seattle Genetics (2003-2008) and VLST (2008-2009). His professional experience includes heading the postdoctoral programs at Genentech (1998-2000), Immunex (2001-2002) and Amgen (2002-2003).

  • Home
  • Privacy & Terms of Use
  • About
  • Board of Directors
  • Advisors
  • Sponsors
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals